Exeltis Pharmaceuticals Holding, S.L. (Spain)

Homepage: exeltis.com

Alternate names: Exeltis, Exeltis Healthcare, Exeltis Pharmaceuticals Holding, S.L.

ROR: 023y4tg36

OpenAlex ID: I4405267308

Bone health in estrogen-free contraception

2019 · P. Hadji, E. Colli, et al. · Osteoporosis International · 118

PDF

Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone‐only pill

2019 · Santiago Palacios, Enrico Colli, et al. · Acta Obstetricia Et Gynecologica Scandinavica · 73

PDF

Chronic Inflammation in PCOS: The Potential Benefits of Specialized Pro-Resolving Lipid Mediators (SPMs) in the Improvement of the Resolutive Response

2020 · Pedro-Antonio Regidor, Anna Mueller, et al. · International Journal of Molecular Sciences · 70

PDF

Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake

2015 · Ingrid J.M. Duijkers, Doris Heger-Mahn, et al. · Contraception · 67

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen

2020 · Thomas Kimble, Anne E. Burke, et al. · Contraception X · 59

PDF

The frequency of endometriosis in the general and selected populations: A systematic review

2020 · Fabio Parazzini, Elena Roncella, et al. · Journal of Endometriosis and Pelvic Pain Disorders · 46

A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg

2019 · Santiago Palacios, Enrico Colli, et al. · Archives of Gynecology and Obstetrics · 44

PDF

Miconazole for the treatment of vulvovaginal candidiasis. In vitro , in vivo and clinical results. Review of the literature

2023 · Pedro Antonio Regidor, Manopchai Thamkhantho, et al. · Journal of Obstetrics and Gynaecology · 38

PDF

Pharmacokinetic bioequivalence, safety and acceptability of Ornibel ® , a new polymer composition contraceptive vaginal ring (etonogestrel/ethinylestradiol 11.00/3.474 mg) compared with Nuvaring ® (etonogestrel/ethinylestradiol 11.7/2.7 mg)

2017 · Jaime Algorta, Maria Diaz, et al. · The European Journal of Contraception & Reproductive Health Care · 38

Development and Validation of an Endometriosis Diagnostic Method Based on Serum Biomarkers and Clinical Variables

2023 · Bárbara Herranz-Blanco, Elza Daoud, et al. · Biomolecules · 37

PDF

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime

2020 · Santiago Palacios, Enrico Colli, et al. · BMC Women s Health · 37

PDF

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg

2020 · S. Palacios, E. Colli, et al. · PLoS ONE · 37

PDF

Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19

2020 · Pedro-Antonio Regidor, Fernando Gonzalez Santos, et al. · Medical Hypotheses · 36

PDF

Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature

2020 · Santiago Palacios, Pedro-Antonio Regidor, et al. · The European Journal of Contraception & Reproductive Health Care · 30

PDF

Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 µg: a double-blind, double-dummy, prospective, randomised study

2021 · Santiago Palacios, Enrico Colli, et al. · The European Journal of Contraception & Reproductive Health Care · 25

PDF

PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs)

2022 · Pedro-Antonio Regidor, Xavier de la Rosa, et al. · Biomedicines · 23

PDF

Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase

2020 · Dan Apter, Enrico Colli, et al. · Contraception · 21

Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females

2019 · W.H. Richter, R. Koytchev, et al. · Contraception · 17

A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg

2024 · Kristina Biskupska-Bodova, Joanna Sójka-Kupny, et al. · The European Journal of Contraception & Reproductive Health Care · 16

Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel

2021 · Pedro-Antonio Regidor, Enrico Colli, et al. · Gynecological Endocrinology · 16

The drospirenone (DRSP)-only pill: clinical implications in the daily use

2023 · Ali Kubba, Kristina Gemzell-Danielsson, et al. · The European Journal of Contraception & Reproductive Health Care · 15

PDF

Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol

2025 · Pedro-Antonio Regidor, Alicyoy Angulo, et al. · Gynecological Endocrinology · 12

Supplementation with myo-inositol and Selenium improves the clinical conditions and biochemical features of women with or at risk for subclinical hypothyroidism

2022 · Juraj Payer, Peter Jackuliak, et al. · Frontiers in Endocrinology · 12

PDF

Oral prolonged-release dienogest 2 mg and ethinylestradiol 0.02 mg in a 24/4-day regimen for polycystic ovary syndrome-associated hirsutism: a double-blind, randomised, placebo-controlled trial

2025 · Roger Lobo, Alicyoy Angulo, et al. · EClinicalMedicine · 10

Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS)

2024 · Asun Gracia Aznar, Fernando Moreno Egea, et al. · Biomedicines · 10

PDF

Works count: 79

Citation count: 1,654